News release from Pharma& – MHRA approval of Pegasys for ET & PV patients

MHRA approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythaemia vera (PV) and essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment for adults with essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment…

In Conversation with… Prof Claire Harrison, considerations for MPN patients when travelling

In this vlogcast, Prof Claire Harrison, Guy’s & St Thomas’ Hospital, London, speaks with Nona about considerations for MPN patients when travelling away from their home city and how to be prepared and cope with change if events cause disruption to travel.  Overall, the discussion emphasizes resilience, practical planning and mental well-being to help MPN…

Update on the availability of Pegasys – 30 May 2025

Since late 2024, there has been a global shortage of Pegasys, the interferon medicine used by many people living with MPNs.  This is due to delays in building a new manufacturing site and gaining the necessary approvals. In the UK, the NHS arranged for patients to be prescribed Besremi as an alternative interferon.  Besremi has…